Seilern Investment Management Ltd disclosed the sale of 70,900 shares of IDEXX Laboratories for the period ended September 30, 2025, an estimated $43.03 million trade based on the average price for Q3 ...
(NYSE: PFE) today announced positive topline results from the Phase 3 HER2CLIMB-05 trial of first-line combination therapy with the tyrosine kinase inhibitor TUKYSA ® (tucatinib) in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback